Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer

Award Number: U01CA263981
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer - ABSTRACT The UTHSCSA group will continue studies during the 2026–2027 extension period focused on identifying active therapeutic agents and rational drug combinations using xenograft models of pediatric sarcoma, liver, and kidney tumors in support of the parent Preclinical Pediatric In Vivo Program (PIVOT) grant (U01263981). These efforts advance the overarching goal of developing rigorous and translationally relevant preclinical testing strategies to prioritize novel therapies for pediatric cancer clinical evaluation. During the current funding period (Year 5), substantial progress has been achieved, including publication of the PIVOT-1816-1 (Vobra Duo) study in Clinical Cancer Research (PMID: 41941262), submission of the Amgen-509 (Xaluritamig; PPTC) manuscript to Cancer Discovery, and preparation of additional manuscripts for PIVOT-2010 (OBI-3424), PIVOT-1817 (DS-7300a), and PIVOT-2011 (SM09419). In addition, seventeen rhabdomyosarcoma (RMS) PDX samples treated with VAC and VI were collected and sequenced for RNA and DNA analyses to investigate mechanisms of acquired resistance. During the requested 12-month extension supported by additional funding, we will complete ongoing studies and advance planned efforts focused on therapeutic testing, molecular characterization, and dissemination of findings. Planned activities include completion of studies associated with PIVOT-1817-3, PIVOT-1818-1, PIVOT- 2041, PIVOT-2035, PIVOT-2047, and PIVOT-2054; uploading and analysis of study data through the PIVOT infrastructure; collaboration with the PIVOT Coordinating Center on company progress reports; and preparation of manuscripts for publication. We will also collaborate with the PIVOT Coordinating Center and Dr. Jeff Chuang on a comprehensive resource manuscript describing PIVOT/Hudson Alpha sequencing and analysis datasets. An additional important objective to be completed in Years 5-6 is the establishment and molecular characterization of 30 new patient-derived xenograft (PDX) models, including 26 germ cell tumor (GCT) models and 4 clear cell sarcoma (CCS) models. These models will undergo RNA sequencing and whole-genome sequencing to expand the molecularly annotated pediatric solid tumor panels available for future preclinical studies. Sequencing and associated analytical datasets generated through these efforts will be submitted to the Childhood Cancer Data Initiative (CCDI), thereby enhancing data accessibility and community resources for pediatric cancer research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $296,542 )
2026	2026	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	001	5	7/14/2026	SUPPLEMENT FOR EXPANSION	$296,542
2026	2025	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	000	5	7/13/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $296,542

Issue Date FY: 2025 ( Subtotal = $593,085 )
2025	2025	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	002	5	5/20/2025	NON-COMPETING CONTINUATION	$593,085
2025	2024	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	001	4	3/25/2025	NON-COMPETING CONTINUATION	$0
2025	2024	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	000	4	11/7/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $593,085

Issue Date FY: 2024 ( Subtotal = $593,085 )
2024	2024	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	001	4	7/22/2024	NON-COMPETING CONTINUATION	$593,085
2024	2023	UNI OF TX HEALTH SCIENCE CTR SAN ANT	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	000	3	1/31/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $593,085

Issue Date FY: 2023 ( Subtotal = $487,604 )
2023	2023	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	000	3	7/14/2023	NON-COMPETING CONTINUATION	$487,604
														Subtotal = $487,604

Issue Date FY: 2022 ( Subtotal = $587,662 )
2022	2022	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	001	2	6/23/2022	NON-COMPETING CONTINUATION	$587,662
2022	2021	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	000	1	3/4/2022	NEW	$0
														Subtotal = $587,662

Issue Date FY: 2021 ( Subtotal = $600,685 )
2021	2021	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	001	1	8/31/2021	NEW	$0
2021	2021	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER OF SAN ANTONIO	7703 FLOYD CURL DR	SAN ANTONIO	TX	78229	BEXAR	USA	Cancer Treatment Research	000	1	8/3/2021	NEW	$600,685
														Subtotal = $600,685

Grand Total All Awards = $3,158,663

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer

Award Number: U01CA263981

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer